The Current Ratio as of November 2024 (TTM) for Innate Pharma S.A. (IPHA) is 2.92

According to Innate Pharma S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 2.92. This represents a change of -12.24% compared to the average of 3.33 of the last 4 quarters.

Innate Pharma S.A. (IPHA) Historical Current Ratio (quarterly & annually)

How has IPHA Current Ratio performed in the past?

The mean historical Current Ratio of Innate Pharma S.A. over the last ten years is 3.26. The current 2.92 Current Ratio has changed 8.87% with respect to the historical average. Over the past ten years (40 quarters), IPHA's Current Ratio was at its highest in in the December 2014 quarter at 7.36. The Current Ratio was at its lowest in in the September 2018 quarter at 1.62.

Innate Pharma S.A. (IPHA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Innate Pharma S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innate Pharma S.A. (IPHA) Average Current Ratio

How has IPHA Current Ratio performed in the past?

The current Current Ratio of Innate Pharma S.A. (IPHA) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Innate Pharma S.A. (IPHA) Current Ratio vs. Peers

How is IPHA’s Current Ratio compared to its peers?

Innate Pharma S.A.’s Current Ratio is less than Eliem Therapeutics, Inc. (60.41), greater than HCW Biologics Inc. (0.07), less than Inhibrx Biosciences, Inc. (4.70), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Pardes Biosciences, Inc. (9.81), less than Shattuck Labs, Inc. (7.96), greater than Champions Oncology, Inc. (0.69), less than Century Therapeutics, Inc. (10.39), less than Addex Therapeutics Ltd (4.97), greater than Aptorum Group Limited (1.18), greater than Celyad Oncology SA (1.42), less than Dyadic International, Inc. (5.15), less than Molecular Partners AG (14.33), less than MediciNova, Inc. (16.66), less than Cyteir Therapeutics, Inc. (21.89),

Build a custom stock screener for Innate Pharma S.A. (IPHA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innate Pharma S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innate Pharma S.A. (IPHA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innate Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.